Key Dosing Patents for Regeneron Retinal Drug Eylea Canceled (2)

Two Regeneron Pharmaceuticals Inc. dosing patents used in the retinal-disease drug Eylea, the source of more than a third of its 2021 revenue, were canceled Wednesday.

The asserted claims of Patent No. 9,669,069 are unpatentable, the Patent Trial and Appeal Board said. The tribunal, an arm of the US Patent and Trademark Office, also voided Patent No. 9,254,338.

Regeneron alleges that a biosimilar version of Eylea proposed by Viatris Inc.'s Mylan Pharmaceuticals Inc. infringes 24 patents. Last week, Regeneron said it won’t seek an injunction based on alleged infringement of all but six of the patents; the voided ...